Blog

  • Implementing Innovation in Healthcare: Learn how to influence change in healthcare delivery

    At this moment in time, we see how critical a high performing healthcare system is to public health and safety; a continuous healthcare improvement approach is vital to achieve this.

    The Implementing Innovation in Healthcare course is an introductory healthcare improvement course aimed at all healthcare workers.

    Through this course, you’ll gain insight into the fields of implementation science, health care improvement and the learning health system, enabling your ability to implement innovation in healthcare.

    The duration of this FREE course is three weeks and commences Monday 3 August. You are welcome to join at any stage throughout the course.

    Learn more or access the course

  • International Alliance of Mental Health Research Funders Survey

    The International Alliance of Mental Health Research Funders (IAMHRF) has asked NHMRC to circulate an invitation to participate in a survey, which aims to help develop a set of common demographic measures to be used in mental health research in a broad range of contexts. The invitation from the IAMHRF follows:

    A serious barrier to understanding mental health conditions has long been the inability to aggregate data across different research efforts. In the wake of COVID, it will be more essential than ever to be able to combine studies and arrive at overall conclusions about the impacts on mental health around the globe. We are asking for your input to help develop a common set of demographic measures to be used in mental health research in a broad range of contexts.

    The Data Harmonization working group of the International Alliance of Mental Health Research Funders (IAMHRF) proposes a minimum set of demographic questions to be collected from funded mental health research projects. The IAMHRF is seeking to promote the uptake of a few shared measures that researchers use alongside any other instruments that may further their research interests so that data aggregation may be simplified across the mental health field.

    Your expertise as a member of the research community is an essential component in successfully harmonizing data collection and advancing the mental health field. We cannot hope to advance a meaningful set of measures without your guidance.

    Please provide your input and help develop a set of common demographic measures here.

    This should take you no longer than 20 minutes to complete.

    The survey will be open until 15 October, 2020.

    We would like to thank you for your interest and essential contribution.

    NHMRC encourages researchers in the mental health field to participate in the survey.

  • $1.8m grant for new rare disease treatment trial offers hope to thousands of sufferers worldwide

    A global research team led by The University of Notre Dame Australia School of Medicine’s Professor Merrilee Needham, in collaboration with the Perron Institute, Fiona Stanley Hospital and Murdoch University was awarded $1.8 million in funding for the trial of a re-purposed drug (Sirolimus) in the treatment of the rare disease Inclusion Body Myositis (IBM).

    Consumer and community members have been at the forefront of this research and contributed to the successful grant application. In total $3.5 million was awarded by the Australian Government investment into 17 cutting-edge research projects.

    “This study will be led from Australia to allow access for as many Australian IBM patients as possible, and we are so delighted to offer our patients a trial of a potential treatment, and more importantly, hope for their future”, Professor Needham said.

    Read the media release from the University of Notre Dame Australia

    Read the media release from Minister for Health Greg Hunt

  • Picture of wellness captured in DETECT Snapshot

    The two-week COVID-19 testing blitz on people not showing symptoms across Western Australia has ended with no positive cases detected.

    The opportunity for people from identified groups to be tested for COVID-19 produced further evidence that there are no undetected cases COVID-19 in the community.

    HBF has committed $2.5 million to the project. HBF’s contribution covers the full costs of DETECT Snapshot and will provide investment in other COVID-19 related research and innovation projects.

    Between Thursday May 28 and Wednesday June 10, 2020, healthcare workers, WA Police staff, school staff, meat workers, and retail, hospitality, transport and tourism industry employees not displaying symptoms of COVID-19 were invited to undergo a swab test for the virus.

    As part of the program 18,409 people stepped forward for testing and all tested negative, with the breakdown of major cohorts as follows:

    • 11,192 health care workers (61%);
    • 2,197 school staff (12%);
    • 1,852 retail workers (10%);
    • 925 hospitality workers (5%); and
    • 875 meat workers (5%);

    WA Police staff, transport workers and tourism industry workers accounted for under 5 per cent each.

    The median age of people tested was 47 years, and 72 per cent were female.

    Just over three quarters of participants reside in the metropolitan area.

    The program was a major co-ordinated effort by public and private pathology providers PathWest, Australian Clinical Labs, Clinipath, and Western Diagnostic Pathology, to offer as many opportunities as possible within the two-week window.

    Testing was offered at more than 100 clinics, drive-through facilities, and pop-up clinics across the State, and on-site testing was facilitated at nearly 200 businesses.

    Read the full media statement

  • CSL opens applications for 2021 Fellowships

    CSL has opened applications for its Centenary Fellowships that are offered to mid-career scientists wanting to undertake medical research at an Australian academic institute.

    The scholarships, which are worth $1.25 million over five years, were established in 2016 to mark CSL’s 100 year anniversary. The ten-year $25 million program is focussed on supporting early-stage translational research.

    “Australia is home to CSL’s global hub for early research and translation medicine and we are committed to helping grow the quality and quantity of Australian research and our biotech ecosystem generally,” said Professor Andrew Cuthbertson AO, CSL’s chief scientific officer.

    “These fellowships are long term, high value, and mid-career. I am confident that the recipients of the CSL Centenary Fellowships will go on to become some of Australia’s most eminent scientists and will lead the next generation of Australian scientific endeavour,” said Professor Cuthbertson.

    There are currently eight active CSL Fellows working at the QIMR Berghofer Institute, the Queensland Brain Institute, the Peter MacCallum Cancer Centre, Baker Heart and Diabetes Institute, Monash University, Murdoch Children’s Research Institute, Menzies School of Health Research and the South Australian Health and Medical Research Institute.

    Their research includes a focus on curing ‘hidden’ malaria, personalised cancer treatment, improving survival rates for patients with acute leukaemia, whether memories are stored in our DNA, liquid biopsies for cancer testing, what really causes arteries to clog, why people die from infection following stroke and vaccines against diseases such as tuberculosis.

    The winners of the 2021 CSL Centenary Fellowships will be announced on 11 October 2021 in conjunction with the annual conference of the Australian Academy of Health and Medical Sciences.

    More information, including application details, is available on the CSL website.

  • Greg Hunt announces $66 million for coronavirus-related research

    Health minister Greg Hunt has announced $66 million in funding for research into vaccine and treatments for COVID-19 and preparations for future pandemics.

    The funding has been made available through the federal government’s Medical Research Future Fund (MRFF) and builds on the $30 million already committed to the Coronavirus Research Response (response).

    The response is part of the federal government’s $8 billion Coronavirus (COVID-19) National Health Plan.

    The response is targeting four research areas – a vaccine, antiviral therapies, clinical trials and improving the health system response and preparedness for future pandemics.

    A vaccine for COVID-19

    The University of Queensland will receive a further $2 million, building on a previously announced $3 million, for its molecular clamp’ technology that can accelerate the development of new vaccines.

    The university is collaborating with a number of biopharmaceutical companies and the Coalition for Epidemic Preparedness Innovations on the development of a COVID-19 vaccine.

    The federal government will also provide a further $13.6 million to support other COVID-19 vaccine development projects in 2020‑21.

    An independent panel of experts will assess expressions of interest and invite formal applications from the most promising projects.

    Antiviral therapies for COVID-19

    The response includes $7.3 million for nine research teams to support the development of antiviral therapies for COVID-19.

    The Walter and Eliza Hall Institute will receive $1 million for the VirDUB research project. The project aims to develop medicines that stop COVID-19 from hijacking human cells and disabling their anti-viral defences.

    Minister Hunt said the most successful projects awarded under this round will have an opportunity to seek additional funding of up to $10 million to accelerate their research.

    Another $2 million is being provided to a project using stem cell-derived tissues to rapidly test drugs already approved for use in humans for activity against COVID-19.

    In the early stages of the program, the Peter Doherty Institute for Infection and Immunity and the Queensland Institute of Medical Research Berghofer will commence this work. Other laboratories will be able to join in the coming months.

    Clinical trials of potential treatments

    The response will provide $6.8 million to support seven clinical trials investigating treatments for the severe respiratory symptoms of COVID-19.

    Improving the health system’s response to COVID-19 and future pandemics

    The University of New South Wales will receive $3.3 million for genomics research into the behaviour, spread and evolution of the SARS-CoV-2 virus.

    Other grant opportunities include $4 million for digital health research infrastructure, $2 million for research into the human immune response to COVID-19 infection, and $600,000 for research to understand the community’s information needs and behavioural drivers during outbreaks.

  • Premier’s Science Fellowship Program

    The Department of Jobs, Tourism, Science and Innovation has extended the submission deadline for applications to the current round of the Premier’s Science Fellowship Program to 2 March 2021.

    This scheme funds a package to support a distinguished researcher and leader of international prominence who must be from interstate or overseas (Premier’s Science Fellow), together with funding for a talented early to mid-career researcher (Premier’s EMC Fellow) who may be from WA, interstate or overseas.

    Each package to be funded in 2021 must address specific areas of strategic importance to WA that fall within one or more of the following priority areas:

    1. Remote asset management
    2. New energy technologies
    3. Mine rehabilitation and closure
    4. Other (Energy, Environment, Food, Health, Mining, Space, Technology)

    To learn more, visit the Premier’s Science Fellowship Program web page.

     

  • $2.9m to boost local researchers’ quest for COVID-19 answers

    Twelve Western Australian research projects have been boosted with funding from the McGowan Government.

    $1.9 million in research grants has been awarded to support COVID-related research projects. Another $1 million has been provided for infrastructure support which will cover costs of consumables, staffing and site set-up for local COVID-19 research.

    The WAHTN were tasked with distributing the funding along with the Department of Health, appointed the Panel including the Chair, Peter Klinken and worked with the research community to best use the $1 million for infrastructure.

    The funding for the 12 research projects will go towards treatments, studies of at-risk groups, development of less invasive tests, study of mental health impacts and tests that will more accurately inform us about immunity of COVID-19.

    One of these projects is a pilot study that will assess the effectiveness of transfusing active COVID-19 cases with plasma from recovered patients (convalescent plasma).

    The pilot, being led by Sir Charles Gairdner Hospital respiratory specialist Dr Anna Tai, will determine whether antibodies contained in donated plasma can prevent patients from deteriorating to the point where they need to be hospitalised or develop Severe Acute Respiratory Syndrome (SARS).

    The project will also see whether such early intervention can reduce the time it takes for the person to feel better or clear the virus from his or her system.

    With Western Australia’s current low number of active cases, Dr Tai is collaborating with other research groups to involve patients from other states and jurisdictions.

    In the absence of a vaccine or treatment for COVID-19, Dr Tai’s study will investigate the therapeutic potential of convalescent plasma in treating COVID-19 patients in the early stages of disease.

    Convalescent plasma has been shown to be effective in managing patients during other major viral outbreaks including the SARS, MERS, Ebola and H1N1 and H5N1 pandemics.

    The full list of recipients is on the Department of Health website.

    The full media statement can be found on the Government of Western Australia’s website.

  • Funding breakthrough for WA health and medical research

    Western Australia is poised to be a leader in the future of health and medicine after the Western Australian Future Fund Amendment (Future Health Research and Innovation Fund) Bill passed State Parliament today.

    The milestone legislation will give Western Australian health and medical researchers and innovators a secure and ongoing source of funding that will include an initial commitment of an extra $37 million over the next three years.

    The legislation repurposes the $1.4 billion WA Future Fund – allowing interest earned on it to be directed to local health and medical research, innovation and commercialisation.

    Under the fund’s ramp-up program the first year’s allocation, expected to be up to $6 million, will be dedicated to COVID-19 research, including the McGowan Government’s nation-leading DETECT program.

    The DETECT program tests selected cohorts of asymptomatic people in order to learn more about COVID-19. It is currently examining education and FIFO groups. Other cohorts being investigated for potential inclusion include health care, aged care, police, retail, hospitality and meat workers.

    Going beyond COVID-19, the increased certainty provided by the Future Health Research and Innovation Fund is expected to help create health sector jobs, diversify the economy, improve patient care, and help Western Australia retain its brightest health researchers, innovators and clinicians, as well as attract global projects and partnerships.

    The full media statement can be found on the Government of Western Australia’s website.

  • NHMRC/MRFF Investigator Grants funding outcomes

    The Minister for Health, the Hon Greg Hunt MP, has announced details of funding for the National Health and Medical Research Council and Medical Research Future Fund Investigator schemes. We would like to congratulate the following researchers on their successful applications:

    NHMRC Investigator Grants

    Duration: 5 years

    Tipping the balance – improving response rates to cancer immunotherapy
    Emerging Leadership 2
    Dr Willem Lesterhuis, Centre for Child Health Research/Telethon Kids Institute
    Total Funded: $1,562,250.00

    Improving patient outcomes in familial hypercholesterolaemia across the continuum of care
    Emerging Leadership 1
    Dr Jing Pang, UWA Medical School
    Total Funded: $645,205.00

    Reducing global mortality and severity of disease in newborn infants through innovation and holistic interventions
    Leadership 2
    Professor Jane Pillow, School of Human Sciences
    Total Funded: $2,060,520.00

     

    MRFF Investigator Grants

    Duration: 5 years

    Better penicillin, better hearts: improving secondary prevention of rheumatic heart disease
    Emerging Leadership 2
    Doctor Laurens Manning, Centre for Child Health Research/Telethon Kids Institute
    Total Funded: $1,281,125.00

    Preventing bronchiectasis in Indigenous people
    Emerging Leadership 2
    Doctor Andre Schultz, Centre for Child Health Research/Telethon Kids Institute
    Total Funded: $1,131,125.00